Oxcia AB (publ) publishes interim report fort the first quarter 2023
First quarter (January-March 2023) Operating loss totaled SEK -16,566,375 (-5 313 134). Loss for the period totaled SEK – 16,450,467 (-5 313 134). Cash flow from operating activities totaled SEK – 6,760,934 (-4 993 784). Earnings per share before dilution totaled SEK -0,76 (-0.25). Earnings per share after dilution amounted to SEK -0.76 (-0.25). Significant events in the first quarter • Thomas Helleday’s Foundation for Medical Research receives approved patent BR112015011497, which includes OXC-101, in Brazil. Oxcia has a lifetime, exclusive license to the